<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01615822</url>
  </required_header>
  <id_info>
    <org_study_id>MMV_OZ439_12_001</org_study_id>
    <nct_id>NCT01615822</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability &amp; Pharmacokinetics (PK) of Co-administered Single Doses of OZ439 and Mefloquine (MQ) in Healthy Volunteers</brief_title>
  <official_title>A Phase I Healthy Volunteer Study Investigating the Safety, Tolerability &amp; Pharmacokinetics of Co-administered Single Doses of OZ439 and Mefloquine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medicines for Malaria Venture</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Cape Town</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medicines for Malaria Venture</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      OZ439 is a novel, synthetic trioxolane medicine which is related to artemisinin, but has the
      advantage of a longer elimination half-life so is being developed to be administered together
      with a potential partner drug e.g. mefloquine as a single dose cure for uncomplicated
      malaria. The study findings will be used to inform the dose and design of future studies. The
      aim of the study is to establish the safety, tolerability and pharmacokinetics of
      co-administered OZ439 and MQ at a range of doses up to the maximum tolerated dose, in healthy
      volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Decision taken to halt progression of mefloquine as a potential partner for OZ439 as a single
    dose cure due to low probability of success
  </why_stopped>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>OZ439 AUC0-t</measure>
    <time_frame>Up to 42 days post-dose</time_frame>
    <description>Area under the plasma concentration versus time curve (AUC) of OZ439</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OZ439 Cmax</measure>
    <time_frame>Up to 42 days post-dose</time_frame>
    <description>Peak Plasma Concentration (Cmax) of OZ439</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MQ AUC0-t</measure>
    <time_frame>Up to 42 days post-dose</time_frame>
    <description>Area under the plasma concentration versus time curve (AUC) of MQ</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MQ Cmax</measure>
    <time_frame>Up to 42 days post-dose</time_frame>
    <description>Peak Plasma Concentration (Cmax) of MQ</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Malaria</condition>
  <arm_group>
    <arm_group_label>OZ439 100mg single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OZ439 100mg single dose oral suspension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OZ439 100mg plus MQ 250mg single doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose OZ439 100mg oral suspension in combination with single dose MQ 250mg tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OZ439 400mg single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OZ439 400mg single dose oral suspension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OZ439 400mg plus MQ 750mg single doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose OZ439 400mg oral suspension in combination with single dose MQ 750mg tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OZ439 100mg</intervention_name>
    <description>OZ439 100mg oral suspension, single dose</description>
    <arm_group_label>OZ439 100mg single dose</arm_group_label>
    <arm_group_label>OZ439 100mg plus MQ 250mg single doses</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OZ439 400mg</intervention_name>
    <description>OZ439 400mg oral suspension, single dose</description>
    <arm_group_label>OZ439 400mg single dose</arm_group_label>
    <arm_group_label>OZ439 400mg plus MQ 750mg single doses</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MQ 250 mg, single dose</intervention_name>
    <description>Mefloquine 250 mg tablet, single dose</description>
    <arm_group_label>OZ439 100mg plus MQ 250mg single doses</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MQ 750mg, single dose</intervention_name>
    <description>Mefloquine 750mg oral tablet, single dose</description>
    <arm_group_label>OZ439 400mg plus MQ 750mg single doses</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and non-childbearing potential female volunteers of between 18 and 55
             years of age

          -  Female volunteers must have a negative serum pregnancy test at screening

          -  Females must be of non-childbearing potential

          -  Male volunteers and their partner(s) must agree to use a double barrier method of
             contraception for at least 14 days prior to first dose of study drug through 90 days
             after the last dose.

          -  Body mass Index between 18 and 30kg/m2, inclusive; and a total body weight &gt;50 kg

          -  Laboratory tests at screening within normal ranges or not clinically significant as
             judged by the Investigator.

        Exclusion Criteria:

          -  Received an investigational drug or participated in another research study within 30
             days of the first dose of study drug or at any time through the study

          -  Evidence of current or history of clinically significant oncologic, pulmonary,
             hepatic, cardiovascular, gastrointestinal, haematologic, metabolic, neurological,
             immunologic, nephrologic, endocrine, psychiatric disease, or clinically significant
             current infection.

          -  Any condition that could possibly affect drug absorption, such as gastrectomy,
             diarrhea and lactose intolerance

          -  Use of any medications, vitamins, herbal supplements, dietary supplements or
             vaccinations within 14 days of the first dose of study drug or at any time through the
             study, unless prior approval is granted. This includes any drugs that are substrates,
             inhibitors or inducers of CYP3A4. Intermittent use of acetaminophen at doses of up to
             2g/day is permitted

          -  History of drug or alcohol abuse within 2 years of Screening

          -  History of alcohol consumption within 24 hours of any study visit

          -  Tobacco users

          -  Consumption of fruit juices within 7 days prior to dosing

          -  Participation in unaccustomed strenuous exercise within 7 days prior to

          -  Positive urine drug screen

          -  Positive test for HIV-1, HBsAg or HCV

          -  Known hypersensitivity to MQ or artemisinins

          -  QTcF greater than 450msec
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen I Barnes</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cape Town</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Division of Clinical Pharmacology, University of Cape Town</name>
      <address>
        <city>Cape Town</city>
        <zip>7925</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 7, 2012</study_first_submitted>
  <study_first_submitted_qc>June 8, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2012</study_first_posted>
  <results_first_submitted>March 17, 2015</results_first_submitted>
  <results_first_submitted_qc>March 17, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 26, 2015</results_first_posted>
  <last_update_submitted>March 27, 2015</last_update_submitted>
  <last_update_submitted_qc>March 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Malaria</keyword>
  <keyword>PK</keyword>
  <keyword>OZ439</keyword>
  <keyword>Mefloquine</keyword>
  <keyword>Healthy Volunteers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mefloquine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cohort 1</title>
          <description>Period 1: OZ439 100mg single dose oral suspension
Period 2: Single dose OZ439 100mg oral suspension in combination with single dose MQ 250mg tablet</description>
        </group>
        <group group_id="P2">
          <title>Cohort 2</title>
          <description>Period 1: OZ439 400mg single dose oral suspension
Period 2: Single dose OZ439 400mg oral suspension in combination with single dose MQ 750mg tablets</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>In Cohort 2, one subject withdrew consent prior to dosing and is therefore not part of the safety population.</population>
      <group_list>
        <group group_id="B1">
          <title>Cohort 1</title>
          <description>Period 1: OZ439 100mg single dose oral suspension
Period 2: Single dose OZ439 100mg oral suspension in combination with single dose MQ 250mg tablet</description>
        </group>
        <group group_id="B2">
          <title>Cohort 2</title>
          <description>Period 1: OZ439 400mg single dose oral suspension
Period 2: Single dose OZ439 400mg oral suspension in combination with single dose MQ 750mg tablets</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.1" spread="10.3"/>
                    <measurement group_id="B2" value="30.6" spread="9.42"/>
                    <measurement group_id="B3" value="26" spread="4.45"/>
                    <measurement group_id="B4" value="28.6" spread="8.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>South Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>OZ439 AUC0-t</title>
        <description>Area under the plasma concentration versus time curve (AUC) of OZ439</description>
        <time_frame>Up to 42 days post-dose</time_frame>
        <population>Only the subjects who completed all treatments in their respective cohort (per-protocol set) were included in the PK population.</population>
        <group_list>
          <group group_id="O1">
            <title>OZ439 100mg Single Dose</title>
            <description>OZ439 100mg single dose oral suspension
OZ439 100mg: OZ439 100mg oral suspension, single dose</description>
          </group>
          <group group_id="O2">
            <title>OZ439 100mg Plus MQ 250mg Single Doses</title>
            <description>Single dose OZ439 100mg oral suspension in combination with single dose MQ 250mg tablet
OZ439 100mg: OZ439 100mg oral suspension, single dose
MQ 250 mg, single dose: Mefloquine 250 mg tablet, single dose</description>
          </group>
          <group group_id="O3">
            <title>OZ439 400mg Single Dose</title>
            <description>OZ439 400mg single dose oral suspension
OZ439 400mg: OZ439 400mg oral suspension, single dose</description>
          </group>
          <group group_id="O4">
            <title>OZ439 400mg Plus MQ 750mg Single Doses</title>
            <description>Single dose OZ439 400mg oral suspension in combination with single dose MQ 750mg tablets
OZ439 400mg: OZ439 400mg oral suspension, single dose
MQ 750mg, single dose: Mefloquine 750mg oral tablet, single dose</description>
          </group>
        </group_list>
        <measure>
          <title>OZ439 AUC0-t</title>
          <description>Area under the plasma concentration versus time curve (AUC) of OZ439</description>
          <population>Only the subjects who completed all treatments in their respective cohort (per-protocol set) were included in the PK population.</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1060" spread="32"/>
                    <measurement group_id="O2" value="1060" spread="32"/>
                    <measurement group_id="O3" value="8100" spread="30"/>
                    <measurement group_id="O4" value="7300" spread="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OZ439 Cmax</title>
        <description>Peak Plasma Concentration (Cmax) of OZ439</description>
        <time_frame>Up to 42 days post-dose</time_frame>
        <population>Only the subjects who completed all treatments in their respective cohort (per-protocol set) were included in the PK population.</population>
        <group_list>
          <group group_id="O1">
            <title>OZ439 100mg Single Dose</title>
            <description>OZ439 100mg single dose oral suspension
OZ439 100mg: OZ439 100mg oral suspension, single dose</description>
          </group>
          <group group_id="O2">
            <title>OZ439 100mg Plus MQ 250mg Single Doses</title>
            <description>Single dose OZ439 100mg oral suspension in combination with single dose MQ 250mg tablet
OZ439 100mg: OZ439 100mg oral suspension, single dose
MQ 250 mg, single dose: Mefloquine 250 mg tablet, single dose</description>
          </group>
          <group group_id="O3">
            <title>OZ439 400mg Single Dose</title>
            <description>OZ439 400mg single dose oral suspension
OZ439 400mg: OZ439 400mg oral suspension, single dose</description>
          </group>
          <group group_id="O4">
            <title>OZ439 400mg Plus MQ 750mg Single Doses</title>
            <description>Single dose OZ439 400mg oral suspension in combination with single dose MQ 750mg tablets
OZ439 400mg: OZ439 400mg oral suspension, single dose
MQ 750mg, single dose: Mefloquine 750mg oral tablet, single dose</description>
          </group>
        </group_list>
        <measure>
          <title>OZ439 Cmax</title>
          <description>Peak Plasma Concentration (Cmax) of OZ439</description>
          <population>Only the subjects who completed all treatments in their respective cohort (per-protocol set) were included in the PK population.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="157" spread="24"/>
                    <measurement group_id="O2" value="147" spread="33"/>
                    <measurement group_id="O3" value="821" spread="21"/>
                    <measurement group_id="O4" value="745" spread="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MQ AUC0-t</title>
        <description>Area under the plasma concentration versus time curve (AUC) of MQ</description>
        <time_frame>Up to 42 days post-dose</time_frame>
        <population>Only the subjects who completed all treatments in their respective cohort (per-protocol set) were included in the PK population.</population>
        <group_list>
          <group group_id="O1">
            <title>OZ439 100mg Plus MQ 250mg Single Doses</title>
            <description>Single dose OZ439 100mg oral suspension in combination with single dose MQ 250mg tablet</description>
          </group>
          <group group_id="O2">
            <title>OZ439 400mg Plus MQ 750mg Single Doses</title>
            <description>Single dose OZ439 400mg oral suspension in combination with single dose MQ 750mg tablets</description>
          </group>
        </group_list>
        <measure>
          <title>MQ AUC0-t</title>
          <description>Area under the plasma concentration versus time curve (AUC) of MQ</description>
          <population>Only the subjects who completed all treatments in their respective cohort (per-protocol set) were included in the PK population.</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="167" spread="18"/>
                    <measurement group_id="O2" value="421" spread="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MQ Cmax</title>
        <description>Peak Plasma Concentration (Cmax) of MQ</description>
        <time_frame>Up to 42 days post-dose</time_frame>
        <population>Only the subjects who completed all treatments in their respective cohort (per-protocol set) were included in the PK population.</population>
        <group_list>
          <group group_id="O1">
            <title>OZ439 100mg Plus MQ 250mg Single Doses</title>
            <description>Single dose OZ439 100mg oral suspension in combination with single dose MQ 250mg tablet</description>
          </group>
          <group group_id="O2">
            <title>OZ439 400mg Plus MQ 750mg Single Doses</title>
            <description>Single dose OZ439 400mg oral suspension in combination with single dose MQ 750mg tablets</description>
          </group>
        </group_list>
        <measure>
          <title>MQ Cmax</title>
          <description>Peak Plasma Concentration (Cmax) of MQ</description>
          <population>Only the subjects who completed all treatments in their respective cohort (per-protocol set) were included in the PK population.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.602" spread="27"/>
                    <measurement group_id="O2" value="1.34" spread="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to Day 42 post-dose</time_frame>
      <desc>All subjects who received at least one dose of study drug were included in the safety analysis set. Adverse events were collected irrespective of whether or not the patients had received OZ439 alone or in combination with MQ.</desc>
      <group_list>
        <group group_id="E1">
          <title>Cohort 1</title>
          <description>Period 1: OZ439 100mg single dose oral suspension
Period 2: Single dose OZ439 100mg oral suspension in combination with single dose MQ 250mg tablet</description>
        </group>
        <group group_id="E2">
          <title>Cohort 2</title>
          <description>Period 1: OZ439 400mg single dose oral suspension
Period 2: Single dose OZ439 400mg oral suspension in combination with single dose MQ 750mg tablets</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Gun Shot wound</sub_title>
                <description>Apart from a single gunshot wound, assessed as unrelated to investigational product, no other serious adverse events (SAEs) were reported</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Motion Sickness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal Conjunctivitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Change of bowel habit</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Gastrointestinal sounds abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Medical Device Site Reaction</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="8"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="10"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal Allergy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Laryngitis Viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nasopharynigitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Tinea Cruris</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Viral Tonsilitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Foreign Body</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ECG QT Shortened</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>GGT Increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Confusional Arousal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Depressive Symptom</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nightmare</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Blister</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Fiona Macintyre, PhD</name_or_title>
      <organization>Medicines for Malaria Venture</organization>
      <phone>+41 22 555 0319</phone>
      <email>macintyref@mmv.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

